TRAIL sensitize MDR cells to MDR-related drugs by down-regulation of P-glycoprotein through inhibition of DNA-PKcs/Akt/GSK-3β pathway and activation of caspases

BACKGROUND: The development of new modulator possessing high efficacy, low toxicity and high selectivity is a pivotal approach to overcome P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in cancer treatment. In this study, we suggest a new molecular mechanism that TRAIL (tumor necrosis fac...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Seo, Suk-Bin, Hur, Jung-Gu, Kim, Mi-Ju, Lee, Jae-Won, Kim, Hak-Bong, Bae, Jae-Ho, Kim , Dong-Wan, Kang, Chi-Dug, Kim, Sun-Hee
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2010
Aiheet:
Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2918570/
https://ncbi.nlm.nih.gov/pubmed/20663232
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-4598-9-199
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia